Dianthus Therapeutics, Inc.
DNTH
$115.96
$6.365.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -60.77% | -79.52% | -67.35% | -42.64% | 17.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.77% | -79.52% | -67.35% | -42.64% | 17.87% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -60.77% | -79.52% | -67.35% | -42.64% | 17.87% |
| SG&A Expenses | 49.29% | 47.71% | 37.35% | 36.63% | 18.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.05% | 55.69% | 66.49% | 62.44% | 84.92% |
| Operating Income | -67.68% | -63.22% | -74.68% | -69.24% | -88.94% |
| Income Before Tax | -67.53% | -72.40% | -91.05% | -88.32% | -102.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.53% | -72.40% | -91.05% | -88.32% | -102.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.53% | -72.40% | -91.05% | -88.32% | -102.46% |
| EBIT | -67.68% | -63.22% | -74.68% | -69.24% | -88.94% |
| EBITDA | -67.72% | -63.26% | -74.73% | -69.29% | -89.01% |
| EPS Basic | -27.57% | -43.40% | -58.36% | -39.78% | 41.27% |
| Normalized Basic EPS | -25.09% | -38.00% | -54.26% | -42.54% | 37.39% |
| EPS Diluted | -27.57% | -43.40% | -58.36% | -39.78% | 41.27% |
| Normalized Diluted EPS | -25.09% | -38.00% | -54.26% | -42.54% | 37.39% |
| Average Basic Shares Outstanding | 32.61% | 19.62% | 19.52% | 32.58% | 79.20% |
| Average Diluted Shares Outstanding | 32.61% | 19.62% | 19.52% | 32.58% | 79.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |